|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 1050 K STREET, NW, #800 |
Address2 |
|
| City | WASHINGTON |
State | DC |
Zip Code | 20001 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 16293-12
|
||||||||
|
6. House ID# 314610000
|
||||||||
| TYPE OF REPORT | 8. Year | 2014 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: William J. Schuyler |
Date | 1/16/2015 4:39:32 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
H.R. 83 - Making consolidated appropriations for the fiscal year ending September 30, 2015, and for other purposes; provisions related to FDA regulation and funding, sequestration, drug importation, ADAP, BARDA and Section 317
H.R. 4800 - Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act of 2015; provisions relating to FDA regulation and funding, sequestration, drug importation
No bill # assigned - Labor, Health and Human Services, Education and Related Agencies Appropriations Act of 2014; provisions related to ADAP, BARDA and Section 317
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Joseph |
McGowan |
|
|
|
Steve |
Scango |
|
|
|
Julie |
Venners Christensen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code CPT
16. Specific lobbying issues
H.R. 2582 - PATENT Jobs Act; provisions related to patent user fees
H.R. 2639 - Patent Litigation and Innovation Act; patent litigation proposols
H.R. 2766 - STOP Act; provisions related to business method patents
H.R. 3116 - MODDERN Cures Act of 2013; Provisions related to exclusivity
H.R. 3309 - Innovation Act; provisions related to patent litigation reform
H.R. 3349 - Innovation Protection Act; provisions related to PTO fee diversion
H.R. 3540 - Demand Letter Transparency Act; provisions related to patent demand letters
H.R. 3709 - Protecting Consumer Access to Generic Drugsprovisions related to patent settlements
H.R. 4287 - Independent Innovator and Repurposing Act; provisions related to patent term restoration
S. 214 - The Preserve Access to Affordable Generics Act; provisions relating to patent settlements
S. 504 - Fair and Immediate Release of Generic Drugs Act; provisions related to patent settlements
S. 866 - Patent Quality Improvement Act of 2013Business methods patents provisions
S. 1013 - Patent Abuse Reduction Act of 2013; provisions related to patent litigation reform
S. 1612 - Patent Litigation Integrity Act; Patent litigation provisions including bonding
S. 1720 - Patent Transparency and Improvements Act
S. 2049 - Transparency in Assertion of Patents Act; Provisions related to patent demand letters
S. 2150 - Independent Innovator and Repurposing Act; provisions related to patent term restoration
S. 2196 - Patent Fee Integrity Act; patent fee diversion prohibition
No bill # assigned - Biopharmaceutical innovation policy issues
No bill # assigned - Biologics data protection issues
No bill # assigned - Intellectual property issues; Additional data exclusivity request that was part of 21st Century Cures submission
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Joseph |
McGowan |
|
|
|
Steve |
Scango |
|
|
|
Julie |
Venners Christensen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 1074 - National Diabetes Clinical Care Commission Act
H.R. 1248 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts
H.R. 1281 - Newborn Screening Saves Lives Reauthorization Act
H.R. 3230 - Veterans' Access to Care through Choice, Accountability, and Transparency Act
H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act; provisions related to antibiotics and drug approval
H.R. 4260 - Ryan White Patient Equity and Choice Act; provisions related to ADAP
H.R. 4847 - End Neglected Tropical Diseases Act
S. 539 - National Diabetes Clinical Care Commission Act
S. 610 - Family Health Care Flexibility Act; provisions relating to reimbursement of OTC drugs under flexible spending and health savings accounts
S. 1165 - Access to Appropriate Immunizations for Veterans Act of 2013; provisions related to extending VA performance measure to include all federally recommended vaccine
S. 1417 - Newborn Screening Saves Lives Reauthorization Act
S. 2917 - Adding Ebola to the FDA Priority Review Voucher Program Act
No bill # assigned - Implementation issues relating to the Patient Protection and Affordable Care Act (PPACA) (Public Law 111-148), including Standards Related to Essential Health Benefits, Actuarial Value, and Accreditation rulemaking
No bill # assigned - 21st Century Cures Initiative and related policy issues
No bill # assigned - FDA special medical use; issues related to limited population antibacterial drug approval pathway
No bill # assigned - FDA accelerated approval policy issues
No bill # assigned - Comparative effectiveness policy issues
No bill # assigned - Biopharmaceutical innovation policy issues
No bill # assigned - Pharmaceutical supply chain security issues
No bill # assigned - 340B policy issues
No bill # assigned - Implementation issues relating to the Physician Payment Sunshine Act
No bill # assigned - Support for COPD national action plan
No bill # assigned - FDA proposed rule regarding generic drug labeling under the 1984 Hatch-Waxman amendments to the FDCA
No bill # assigned - FDA proposed rule regarding Electronic Distribution of Content of Labeling for Human Prescription Drug and Biological Products
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Joseph |
McGowan |
|
|
|
Steve |
Scango |
|
|
|
Julie |
Venners Christensen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 351 - Protecting Seniors' Access to Medicare Act of 2013; provisions related to the Independent Payment Advisory Board
H.R. 928 - Medicare Prescription Drug Savings and Choice Act of 2013; provisions related to Medicare Part D
H.R. 1024 - Medication Therapy Empowerment Act of 2013; provisions related to Part D issues
H.R. 1102 - Medicare Prescription Drug Price Negotiation Act of 2013; Provisions related to Part D issues and non-interference
H.R. 1588 - Medicare Drug Savings Act of 2013; provisions related to Part D issues
H.R. 2810 - Medicare Patient Access and Quality Improvement Act of 2013; Provisions related to SGR reform
H.R. 2827 - To amend title XVIII of the Social Security Act to allow for fair application of the exceptions process for drugs in tiers in formularies in prescription drug plans under Medicare part D; provisions related to Medicare Part D Drug Tier Formularies
H.R. 3890 - Better Care, Lower Cost Act; Provisions related to Part D, value-based insurance design, and chronic disease
H.R 4160 - Keep the Promise to Seniors Act of 2014; provisions related to Part D
H.R. 4187 - Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms (DISARM) Act
H.R. 4302 - Protecting Access to Medicare Act of 2014; provisions related to the biopharmaceutical industry
S. 117 - Medicare Prescription Drug Price Negotiation Act of 2013; provisions related to Part D issues
S. 351 - Protecting Seniors' Access to Medicare Act of 2013; provisions related to the Independent Payment Advisory Board
S. 408 - Medicare Prescription Drug Savings and Choice Act of 2013; provisions related to Medicare Part D
S. 557 - Medication Therapy Empowerment Act of 2013; provisions related to Part D issues
S. 740 - Medicare Drug Savings Act of 2013; provisions related to Part D issues
S. 1871 - SGR Repeal and Medicare Beneficiary Access Act of 2013; Provisions related to reforming Medicare physician payments
S. 1932 - Better Care, Lower Cost Act; Provisions related to Part D, value-based insurance design, and chronic disease
S. 2000 - SGR Repeal and Medicare Provider Payment Modernization Act of 2014; Provisions related to SGR reform
S. 2110 - Medicare SGR Repeal and Beneficiary Access Improvement Act of 2014; Provisions related to SGR reform
No bill # assigned - Contract Year 2015 Policy and Technical Cganges to the Medicare Advantage and the Medicare Prescription Drug Benefits Programs; Provisions related to Part D
No bill # assigned - Proposals to increase co-payments for Part D beneficiaries receiving the low-income subsidy
No bill # assigned - Issues related to better use of medicines and comprehensive medication management
No bill # assigned - Medicaid Program, Covered Outpatient Drugs rulemaking
No bill # assigned - Implementation Issues relating to the Physician Payment Sunshine ActNo bill # assigned - Vaccine access and coverage issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Joseph |
McGowan |
|
|
|
Steve |
Scango |
|
|
|
Julie |
Venners Christensen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
H.R. 4438 - A bill to modify and make permanent the research and development (R&D) tax credit
H.R. 5771 - Tax Increase Prevention Act of 2014; provisions related to extension of the research and development tax credit
S. 2786 - Corporate Inverters Earnings Stripping Reform Act of 2014; provisions related to Internal Revenue Code section 163(j)
No bill # assigned - Tax reform policy issues; provisions related to corporate tax reform and research and development tax credit
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Joseph |
McGowan |
|
|
|
Steve |
Scango |
|
|
|
Julie |
Venners Christensen |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAR
16. Specific lobbying issues
H.R. 6727 - U.S. Job Creation and Manufacturing Competitiveness Act of 2013; provisions related to the emporary duty suspension for preparations, such as tablets or chewing gum, intended to assist smokers to stop smoking (provided for in subheading
2106.90.99)
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Gary |
Heimberg |
|
|
|
Steve |
Scango |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TRD
16. Specific lobbying issues
H.R. 3830 - Bipartisan Congressional Trade Priorities Act of 2014; provisions related to trade agreeemnts
S. 1900 - Bipartisan Congressional Trade Priorities Act of 2014; provisions related to trade agreeemnts
No bill # assigned - Trans-Pacific Strategic Economic Partnership Agreement (TPP); provisions related to intellectual property, market access and public health issues
No bill # assigned - Transatlantic Trade and Investment Partnership (TTIP); provisions related to market access intellectual property, regulatory harmonization and other issues
No bill # assigned - International market access and intellectual property issues
No bill # assigned - Canada IP and market access issues
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES, U.S. Trade Representative (USTR)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
William |
Schuyler |
|
|
|
Sarah |
Walsh |
|
|
|
Kimberly |
Williams |
|
|
|
Gary |
Heimberg |
|
|
|
Joseph |
McGowan |
|
|
|
Steve |
Scango |
|
|
|
Julie |
Venners Christensen |
|
|
|
Shira |
Kilcoyne |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address | |
||||||
| City | |
State | |
Zip Code | |
Country | |
21. Client new principal place of business (if different than line 20)
| City | |
State | |
Zip Code | |
Country | |
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |